Skip to content
MedsAcross

Medicine

Desloratadine 5 mg tablet

Available on requestPrescription onlyUS FDAGeneric name

Desloratadine 5 mg tablet is a generic prescription medicine for oral use, made by 7 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Store at 20° to 25°C (68° to 77°F). Avoid exposure at or above 30ºC (86ºF)…

Key facts

Active ingredient (INN)
Desloratadine
Brand
Sold under the generic name
Strength
5 mg
Dosage form
Tablet
Route
Oral
Packs
100 tablets, 500 tablets, 90 tablets and 17 more
Manufacturers
LupinIndiaNatco PharmaIndiaBryant Ranch PrepackA-S Medication SolutionsBionpharmaMorepen BioVirtus Pharmaceuticals
Origin register
US FDA, United States
Storage
Store at 20° to 25°C (68° to 77°F). Avoid exposure at or above 30ºC (86ºF). Protect from moisture.
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
ATC code
R06AX27 Desloratadine
HS code (indicative)
3004.90Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
25 February 2013
Identifiers
RxCUI 349420DailyMed set ID e4db30a5-48e5-4fe3-8793-30b6866f87c1, 0fe374d0-c14b-4102-b568-eb79165fc7ef, 69b9635b-c790-4316-a790-67b0f5512b72 +7NDC 69339-194, 69543-107, 50090-4794 +7Application ANDA078351, ANDA078355, ANDA078352 +1

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

Packs from every labeler of this generic presentation.

PackCodeLabelerMarketed since
100 tablet, film coated in 1 bottle68180-153-01LupinIndia25 February 2013
500 tablet, film coated in 1 bottle68180-153-02LupinIndia25 February 2013
100 tablet, film coated in 1 bottle69339-194-01Natco PharmaIndia1 April 2026
500 tablet, film coated in 1 bottle69339-194-05Natco PharmaIndia1 April 2026
100 tablet, film coated in 1 bottle, plastic69452-363-20Bionpharma28 November 2023
500 tablet, film coated in 1 bottle, plastic69452-363-30Bionpharma28 November 2023
100 tablet in 1 bottle87717-001-01Morepen Bio27 August 2026
500 tablet in 1 bottle87717-001-02Morepen Bio27 August 2026
100 tablet in 1 bottle, plastic69543-107-10Virtus Pharmaceuticals12 June 2015
500 tablet in 1 bottle, plastic69543-107-50Virtus Pharmaceuticals12 June 2015
90 tablet in 1 bottle50090-3975-0A-S Medication Solutions13 December 2018
30 tablet in 1 bottle50090-3975-1A-S Medication Solutions6 December 2018
90 tablet, film coated in 1 bottle50090-4794-0A-S Medication Solutions12 December 2019
90 tablet, film coated in 1 bottle50090-6724-0A-S Medication Solutions5 October 2023
30 tablet, film coated in 1 bottle71335-1000-1Bryant Ranch Prepack13 November 2018
90 tablet, film coated in 1 bottle71335-1000-2Bryant Ranch Prepack9 April 2024
60 tablet, film coated in 1 bottle71335-1000-3Bryant Ranch Prepack9 April 2024
100 tablet in 1 bottle, plastic72162-2308-1Bryant Ranch Prepack7 May 2024
30 tablet in 1 bottle, plastic72162-2308-3Bryant Ranch Prepack7 May 2024
500 tablet in 1 bottle, plastic72162-2308-5Bryant Ranch Prepack7 May 2024

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 21 December 2001Drugs@FDA
EU (EMA)AuthorisedEMA medicines data
India (CDSCO)Not yet confirmed against CDSCO approval lists—
AustriaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
BelgiumRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
BulgariaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CroatiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CyprusRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CzechiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
DenmarkRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
EstoniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
FinlandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
FranceRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
GermanyRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
GreeceRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
HungaryRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
IcelandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
IrelandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
ItalyRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LatviaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LiechtensteinRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LithuaniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LuxembourgRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
MaltaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
NetherlandsRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
NorwayRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
PolandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
PortugalRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
RomaniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SlovakiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SloveniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SpainRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SwedenRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Alternatives

Other makers and brands of Desloratadine 5 mg tablet.

Compare 1

Other strengths and forms of Desloratadine

Clinical summary

Desloratadine is a histamine-1 receptor antagonist indicated for seasonal Allergic Rhinitis, among other approved uses. It is available as tablets, orally disintegrating tablets and oral solution. MedsAcross supplies Desloratadine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Desloratadine

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Desloratadine 5 mg tablet for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.